公开(公告)号：EP2131815A1

公开(公告)日：2009-12-16

申请号：EP08732476.0

申请日：2008-03-19

申请人： Alkermes, Inc.

发明人： KUMAR, Rajesh ,  TROIANO, Gregory ,  RAMSTACK, J., Michael ,  HERBERT, Paul ,  FIGA, Michael

IPC分类号： A61K9/14

CPC分类号： A61K9/1647 ,  A61K9/1623 ,  A61K9/1682 ,  A61K9/5031 ,  A61K9/5089 ,  A61K38/2278

摘要： Methods of forming compositions for the sustained release of water soluble active agents, including biologically active polypeptides and products produced by the process are described. Improved product characteristics and ease of scale-up can be achieved using a novel coacervation process wherein at least one coacervation agent is added to the mixture comprising the active agent and the polymer in at least two distinct stages.

公开(公告)号：EP1983991A2

公开(公告)日：2008-10-29

申请号：EP07762627.3

申请日：2007-02-01

申请人： Alkermes, Inc.

发明人： EHRICH, Elliot

IPC分类号： A61K31/485 ,  A61K9/22 ,  A61P25/32

CPC分类号： A61K45/06 ,  A61K31/195 ,  A61K31/473 ,  A61K2300/00

摘要： The current invention provides methods of treating alcohol related disorders by providing a sustained release oral drug dosage form comprising a plurality of solid state drugs i.e., baclofen and naltrexone, dispersed in a solid state unitary matrix formed from a combination of swellable polymers. The combination of swellable polymers in a single oral drug dosage form is beneficial in terms of release rate control for combination therapies.

公开(公告)号：EP1660037A4

公开(公告)日：2008-09-24

申请号：EP04779411

申请日：2004-07-29

申请人： ALKERMES INC

发明人： BROWN JOSIAH

IPC分类号： A61K9/08 ,  A61K9/10 ,  A61K31/496 ,  A61K47/02 ,  A61K47/26 ,  A61K47/38

CPC分类号： A61K9/0019 ,  A61K9/10 ,  A61K31/496 ,  A61K47/02 ,  A61K47/26 ,  A61K47/38

摘要： The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a polylactide-co-glycolide microsphere formulation containing the active agent. This surprising result provides pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture of microspheres.

公开(公告)号：EP1485154B1

公开(公告)日：2008-05-07

申请号：EP02807120.7

申请日：2002-10-10

申请人： Alkermes, Inc.

发明人： EDWARDS, David ,  ELLWANGER, Colleen ,  FOSHEE, David, L. ,  DURKIN, Jason, R. ,  COKER, Timothy, B. ,  STAPLETON, Kevin ,  DREESEN, Sarah ,  DELONG, Mark ,  JONES, Andrew ,  MCMANUS, Ryan ,  SAUNDERS, Margaret, Millar ,  SPALLER, Robert, W. ,  ZIEGLER, Andrew

IPC分类号： A61M15/00

CPC分类号： A61M15/0028 ,  A61M15/0041 ,  A61M15/0068 ,  A61M2202/064

摘要： A puncturing device (1600) for puncturing of a wall, in particular the wall of a capsule containing medication for inhalation. The puncturing device or assembly comprises one or more substantially longitudinal prongs (1620), each having a puncturing surface (1630) at its distal end as well as a primary cutting edge (1640) disposed on the periphery of the prong and terminating at the puncturing surface (1630). A substantially planar face (1650) is disposed on the periphery of each prong (1620) opposite of the primary cutting edge (1640).

公开(公告)号：EP1210942B1

公开(公告)日：2007-03-21

申请号：EP02075905.6

申请日：1997-05-06

申请人： Alkermes, Inc. ,  JANSSEN PHARMACEUTICA N.V.

发明人： Rickey, Michael E. ,  Ramstack, J. Michael ,  Lewis, Danny H. ,  Mesens, Jean Louis

IPC分类号： A61K9/16 ,  A61K9/50 ,  A61K31/517

CPC分类号： A61K9/1647 ,  A61K9/1694 ,  B01J13/02

公开(公告)号：EP0585412B1

公开(公告)日：1999-07-07

申请号：EP92917463.9

申请日：1992-04-23

申请人： ALKERMES, INC.

发明人： KOZARICH, John, W. ,  MUSSO, Gary, F. ,  MALFROY-CAMINE, Bernard

IPC分类号： C07K7/02 ,  C07K7/18 ,  A61K38/08 ,  A61K47/42

CPC分类号： A61K38/043 ,  A61K38/08 ,  A61K47/42 ,  C07K7/02 ,  C07K7/18 ,  Y10S514/929 ,  A61K2300/00

摘要： Peptides called receptor mediated permeabilizers (RMP) increase the permeability of the blood/brain barrier to molecules such as therapeutic agents or diagnostic agents. The permeabilizer A-7 or conformational analogues can be intravenously coadministered to a host together with molecules whose desired destination is the interstitial fluid compartment of the brain. Alternatively, the permeabilizer A-7 or conformational analogues can be administered sequentially with the molecule(s) of interest and these molecules can also be administered by routes other than intravascular. The permeabilizer A-7 or conformational analogues allow these molecules to penetrate the blood-brain barrier and arrive in the interstitial fluid.

公开(公告)号：EP0885900A2

公开(公告)日：1998-12-23

申请号：EP98113628.6

申请日：1992-04-23

申请人： ALKERMES, INC.

发明人： Kozarich, John W. ,  Musso, Gary F. ,  Malfroy-Camine, Bernard

IPC分类号： C07K7/02 ,  C07K7/18 ,  A61K38/08 ,  A61K47/42

CPC分类号： A61K38/043 ,  A61K38/08 ,  A61K47/42 ,  C07K7/02 ,  C07K7/18 ,  Y10S514/929 ,  A61K2300/00

摘要： Peptides called receptor mediated permeabilizers (RMP) increase the permeability of the blood/brain barrier to molecules such as therapeutic agents or diagnostic agents. The permeabilizer A-7 or conformational analogues can be intravenously coadministered to a host together with molecules whose desired destination is the interstitial fluid compartment of the brain. Alternatively, the permeabilizer A-7 or conformational analogues can be administered sequentially with the molecule(s) of interest and these molecules can also be administered by routes other than intravascular. The permeabilizer A-7 or conformational analogues allow these molecules to penetrate the blood-brain barrier and arrive in the interstitial fluid.

摘要翻译： 肽称为受体介导的permeabilizers（RMP）增加血/脑屏障的分子的渗透性：如治疗剂或诊断剂。 所述渗透剂A-7或构象的类似物可经静脉内连同分子，其希望的目的地是脑的间质液隔室共同施用至宿主。 可替代地，渗透剂A-7或构象类似物可与兴趣和合成分子的分子（多个）被依次施用因此，可以通过血管内比其它途径给药。 所述渗透剂A-7或构象类似物允许合成分子穿透血 - 脑屏障，并在间质液到达。

公开(公告)号：EP0758899A1

公开(公告)日：1997-02-26

申请号：EP95916367.0

申请日：1995-04-20

申请人： ALKERMES, INC.

发明人： GRANEY, William F.

IPC分类号： A61K38 ,  A61K45 ,  A61K49 ,  A61P9 ,  A61P27 ,  A61P31 ,  A61P43

CPC分类号： A61K38/043 ,  A61K2300/00

摘要： The permeability of the blood-ocular barrier to therapeutic or diagnostic agents in the bloodstream of a host is increased by administering a permeabilizer peptide, preferably bradykinin or a bradykinin analogue, into the bloodstream of a host. The invention provides methods of treatment or diagnosis of ocular diseases by administration of a permeabilizer peptide, such as permeabilizer A-7, in combination with a therapeutic or diagnostic agent.

公开(公告)号：EP3570834B1

公开(公告)日：2021-12-22

申请号：EP18702839.4

申请日：2018-01-11

发明人： FULLER, Nathan, Oliver ,  LOWE, John, A., III

IPC分类号： A61K31/437 ,  A61K31/519 ,  A61P25/28

公开(公告)号：EP2252150B1

公开(公告)日：2018-04-11

申请号：EP09710456.6

申请日：2009-02-13

申请人： Alkermes, Inc.

发明人： ARNELLE, Derrick ,  DEAVER, Daniel ,  DEAN, Reginald, L., III ,  TODTENKOPF, Mark

IPC分类号： A01N43/42 ,  A61K31/44

CPC分类号： A61K31/485 ,  A61K31/4748 ,  A61K45/06 ,  C07D471/08 ,  C07D489/08

摘要： The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to morphinan compounds useful as μ, δ, and/or &kgr; receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.